Key result
Management of chronic stable angina involves lifestyle changes, pharmacotherapy with agents like beta-blockers or ranolazine, and invasive strategies for patients unresponsive to medical therapy.
Management of chronic stable angina requires a comprehensive approach including lifestyle modifications, antianginal pharmacotherapy, and consideration of invasive strategies for refractory symptoms.
Affirms lifestyle and pharmacotherapy first for stable angina; leaves open optimal criteria for invasive escalation.
Key Clinical PointsChronic Stable Angina In patients with suspected angina, it is important not only to make a diagnosis, but also to assess the prognosis. Management of angina should include lifestyle changes and pharmacotherapy to reduce cardiovascular risks, including those associated with high blood pressure and elevated lipid levels. Standard antianginal medications include beta-blockers, long-acting nitrates, and calcium-channel blockers; ranolazine is a new agent approved by the Food and Drug Administration for angina. Relief of angina should be assessed again within 2 weeks after the initiation of therapy. An invasive strategy is a reasonable option in patients who do not have a response to medical therapy. Physiological assessment of the target lesion is useful to guide decisions regarding revascularization.
No takes yet. Share an insight, caveat, or question.
Dörler et al. (2016) conducted a review in Chronic Stable Angina. Management of chronic stable angina was evaluated. Management of chronic stable angina involves lifestyle changes, pharmacotherapy with agents like beta-blockers or ranolazine, and invasive strategies for patients unresponsive to medical therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: